Potential hepatotoxicity of efavirenz and saquinavir/ritonavir coadministration in healthy volunteers

Archives of Drug Information

Volumn 2, Issue 1, 2009, Pages 1-7

  Jamois, Candice ^a   Riek, Myriam ^a   Schmitt, Christophe ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug interaction; Efavirenz; Human immunodeficiency virus; Pharmacokinetics; Ritonavir; Saquinavir

Indexed keywords

EFAVIRENZ; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LEUKOCYTOSIS; LIVER DISEASE; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL ASSESSMENT; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN; VOLUNTEER; VOMITING;

EID: 77953376266     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2009.00016.x     Document Type: Article

References (13)

1. Sustiva® (Efavirenz) Capsules and Tablets. Available at: http://packageinserts.bms.com/pi/pi_sustiva.pdf (accessed October 3, 2008).
2. Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000; 30: 313-8.
3. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999; 20: 147-69.
4. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29-33.
5. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26: 552-61.
6. Kurowski M, Sternfeld T, Sawyer AW, Goldbach J, Möchlinghoff C. Minor interaction between efavirenz and saquinavir, when combined with small doses of ritonavir in a q.d. regimen. Paper presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens, Greece.
7. Piliero PJ, Preston SL, Japour A, Stevens RC, Morvillo C, Drusano GL. Pharmacokinetics (PK) of the combination of ritonavir (RTV) plus saquinavir (SQV), with and without efavirenz (EFV) in healthy volunteers. Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL, USA.
8. Piketty C, Race E, Castiel P, et al. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. AIDS 2000; 14: 626-8.
9. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100mg) in combination with efavirenz: Pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32: 240-2.
10. Grange S, Schutz M, Schmitt C, Riek M, Gaudeul-Ehrhart E. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa. Paper presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec, Canada.
11. Boyd M, Autar R, Siangphoe U, et al. Saquinavir 1000 mg BID boosted with ritonavir 200mg in the presence of efavirenz 600mg results in adequate saquinavir minimum concentrations: HIV-NAT 012 pharmacokinetic study. Paper presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy.
12. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001; 184: 37-42.
13. Kaeser B, Zandt H, Deraet M, et al. Ritonavir boosted saquinavir-ketoconazole drug-drug interaction. Paper presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL, USA.